ANA: What This Test Actually Measures

What the ANA Test Physically Measures

The ANA test identifies antibodies in a patient's serum that attach to antigens located inside cell nuclei. Most clinical laboratories use indirect immunofluorescence (IIF) on HEp-2 (human epithelial type 2) cells as the standard method, because HEp-2 cells are large, easy to visualize, and express a wide range of nuclear antigens. The American College of Rheumatology recommends IIF as the gold-standard screening method for ANA.

The Biology Behind the Test

In healthy immune function, the body tolerates its own nuclear proteins. When tolerance breaks down, B cells produce autoantibodies against double-stranded DNA (dsDNA), histones, Sm antigen, SSA/Ro, SSB/La, Scl-70, centromere proteins, and dozens of other nuclear targets. The ANA test does not identify which specific antigen is bound. It detects the aggregate signal from all nuclear-binding antibodies present in a diluted serum sample.

How the Laboratory Runs the Test

A technician layers the patient's diluted serum onto a glass slide coated with HEp-2 cells. If the serum contains antinuclear antibodies, they bind to the cells. A fluorescein-labeled anti-human IgG reagent is then applied; it attaches to any human antibodies already bound to the nuclei. Under ultraviolet light, positive slides glow. The technician records the highest serum dilution at which fluorescence is still visible. That dilution is the titer. This procedural standard is described in detail by the ACR's position statement on ANA testing methodology.

Why Titer Matters More Than Positive or Negative

A positive ANA at 1:40 means fluorescence was detectable when the serum was diluted 40-fold. At 1:160, the serum is diluted 160-fold and signal is still present, indicating a much higher antibody concentration. The clinical significance scales with the titer. A 2019 analysis published in Annals of the Rheumatic Diseases found that, among patients ultimately diagnosed with SLE, median ANA titers were 1:320 or higher at presentation, while healthy positive controls clustered overwhelmingly at 1:40 to 1:80. Titers below 1:80 have limited diagnostic value in most clinical contexts.

What a Normal ANA Range Looks Like

"Normal" for ANA is not a single number. The result depends on the titer threshold chosen, the assay platform, and the population being tested. A landmark population study by Satoh et al. (2012) in Arthritis and Rheumatism tested 4,754 healthy U.S. Adults and found ANA positivity (at 1:40) in 13.8% of women and 9.6% of men. At a threshold of 1:160, positivity dropped to approximately 3.0% across the population.

Standard Titer Reference Points

| Titer | Approximate prevalence in healthy adults | Clinical interpretation | |---|---|---| | <1:40 | ~86-90% of healthy adults | Negative; no significant ANA activity | | 1:40 | ~10-14% of healthy adults | Low positive; often not clinically meaningful | | 1:80 | ~6-8% | Borderline; interpret with clinical context | | 1:160 | ~3% | Positive; warrants reflex antibody testing | | ≥1:320 | <1% | High positive; strong association with connective-tissue disease |

A negative ANA is reported simply as negative or <1:40. Most guidelines, including the 2019 European League Against Rheumatism (EULAR) recommendations on SLE classification, require ANA positivity at 1:80 or above as an entry criterion for the SLE classification score. The 2019 EULAR/ACR SLE classification criteria specify a 1:80 threshold on HEp-2 cells or an equivalent positive test.

Age and Sex Effects on Baseline ANA Rates

ANA positivity rises with age even in people without autoimmune disease. The Satoh population study found that adults over 65 had ANA positivity rates roughly twice those of adults under 40, independent of any diagnosed illness. Women test positive more often than men at every age. These demographic patterns mean a 1:40 result in a 70-year-old woman with no joint symptoms carries far less weight than the same result in a 28-year-old woman presenting with malar rash, arthritis, and fatigue.

ANA Patterns: What the Fluorescence Shape Tells the Clinician

The fluorescence pattern seen under the microscope adds clinical information beyond the titer alone. Patterns are standardized by the International Consensus on ANA Patterns (ICAP), which classifies more than 30 distinct morphologies. The ICAP classification system, described in detail by Damoiseaux et al. (2019) in Autoimmunity Reviews, provides the current international reference for ANA pattern reporting.

The Five Most Common Patterns

Homogeneous (AC-1). Uniform nuclear staining. Associated with anti-dsDNA and anti-histone antibodies. Most common pattern in SLE and drug-induced lupus.

Speckled (AC-4, AC-5). Discrete dots throughout the nucleus. Associated with anti-Sm, anti-SSA/Ro, anti-SSB/La, anti-RNP, and anti-Scl-70 antibodies depending on speckle size and distribution. Seen in SLE, Sjögren syndrome, mixed connective-tissue disease, and systemic sclerosis.

Nucleolar (AC-8, AC-9, AC-10). Staining concentrated in the nucleolus. Strongly associated with systemic sclerosis (scleroderma) and polymyositis.

Centromere (AC-3). Discrete dots numbering 46 in dividing cells, corresponding to chromosomal centromeres. Characteristic of limited systemic sclerosis (CREST syndrome).

Cytoplasmic patterns (AC-16 through AC-21). Technically outside the nucleus but detected on the same HEp-2 slide. Include anti-mitochondrial patterns (primary biliary cholangitis) and anti-Jo-1 patterns (antisynthetase syndrome with inflammatory myopathy).

Why Pattern Alone Does Not Diagnose

Pattern guides, but does not replace, specific antibody testing. A homogeneous pattern at 1:320 in a woman with photosensitive rash, nephritis, and lymphopenia is a strong signal for SLE. The same pattern at 1:80 in an otherwise healthy person getting a pre-employment physical is almost always a false positive in the disease-specific sense. The clinician's job is to combine titer, pattern, and clinical picture before ordering the next test.

What a High ANA Means

A high ANA titer (1:160 or above) means that a measurable concentration of antinuclear antibodies is circulating in the blood. It does not mean the patient has lupus. Roughly 97% of people with SLE test ANA-positive, but only a small fraction of all people with a positive ANA have SLE. A study in Arthritis Care and Research estimated that a positive ANA has a positive predictive value of only 11-13% for SLE in an unselected clinic population.

Conditions Associated with a High ANA

• Systemic lupus erythematosus (SLE): ANA sensitivity approximately 97-98% per ACR criteria
• Sjögren syndrome: 48-96% ANA positive depending on the cohort
• Systemic sclerosis (scleroderma): 85-98% ANA positive
• Polymyositis / dermatomyositis: 40-80% ANA positive
• Mixed connective-tissue disease (MCTD): >95% ANA positive
• Rheumatoid arthritis: 20-40% ANA positive, usually low titer
• Autoimmune hepatitis: 50-80% ANA positive
• Drug-induced lupus: nearly 100% ANA positive while drug is active
• Healthy individuals with no diagnosis: up to 13% at low titer

Drugs That Can Cause a False-Positive or Elevated ANA

Hydralazine, procainamide, isoniazid, minocycline, and anti-TNF biologics (particularly infliximab and etanercept) are well-documented causes of drug-induced ANA elevation. Borchers et al. Reviewed drug-induced lupus in Seminars in Arthritis and Rheumatism and identified procainamide and hydralazine as the agents most likely to produce clinical drug-induced lupus alongside a positive ANA. Stopping the offending drug typically causes the ANA to fall and symptoms to resolve over weeks to months, though the timeline varies.

What the Clinician Does Next After a High ANA

A positive ANA at 1:160 or above triggers reflex testing for specific extractable nuclear antigens (ENAs) and dsDNA antibodies. The reflex panel typically includes anti-dsDNA, anti-Sm, anti-SSA/Ro, anti-SSB/La, anti-Scl-70, anti-Jo-1, and anti-centromere. Each has a different disease association and different sensitivity/specificity profile. Anti-dsDNA and anti-Sm are highly specific for SLE (>95% specificity). Anti-SSA/Ro and anti-SSB/La are more often seen in Sjögren syndrome. The ACR's 2020 updated recommendations for SLE classification cite anti-dsDNA above 3 standard deviations of the laboratory mean as a high-specificity marker that contributes significantly to the classification score.

What a Low or Negative ANA Means

A negative ANA result makes SLE very unlikely but does not completely exclude it. The test has approximately 97% sensitivity for SLE. Three patients in every hundred with active SLE may test ANA-negative, particularly those with anti-SSA/Ro antibodies but no broad antinuclear activity. Kavanaugh et al., writing in Arthritis and Rheumatism, noted that ANA-negative lupus accounts for roughly 1-3% of SLE cases and is often associated with isolated anti-SSA/Ro or anti-SSB/La positivity.

Clinical Situations Where a Negative ANA Does Not Fully Rule Out Autoimmune Disease

A low or negative ANA does not exclude Sjögren syndrome in all presentations, because some anti-SSA/Ro-positive patients have IgA-class antibodies that IIF does not detect well. It also does not exclude antiphospholipid syndrome, inflammatory myopathy with anti-SRP or anti-MDA5 antibodies, or vasculitis. If clinical suspicion remains high despite a negative ANA, the workup should continue with targeted antibody panels rather than stopping at the ANA alone.

Can ANA Be Lowered or Raised?

Lowering ANA

No therapy targets ANA directly. The antibody titer often falls when the underlying disease is treated effectively. In SLE, hydroxychloroquine (400 mg/day as the standard initial dose per ACR guidelines) reduces disease activity and, in some longitudinal cohorts, correlates with gradual titer reduction over 12-24 months. Fessler et al. Showed in a 2005 Arthritis and Rheumatism study that hydroxychloroquine use was associated with significantly lower rates of ANA-related flares over 3 years of follow-up. Immunosuppressants such as mycophenolate mofetil, azathioprine, and belimumab can reduce overall autoantibody burden in active SLE, but ANA normalization is not a standard treatment endpoint. Clinicians monitor anti-dsDNA and complement levels (C3, C4) as activity markers more than they track total ANA titer.

Raising ANA

There is no clinical reason to deliberately raise an ANA level. A higher ANA does not confer any health benefit. The test is purely a diagnostic signal. Patients sometimes ask whether lifestyle changes, supplements, or hormonal therapies will affect their ANA; outside of the drug-induced causes described above, no randomized evidence shows that common interventions change ANA titer in clinically meaningful ways.

How Hormone and Metabolic Status Intersect with ANA Testing

Sex Hormones and Autoantibody Production

SLE affects women at approximately 9 times the rate of men, a disparity that strongly implicates sex hormones. Estrogen appears to promote B-cell survival and reduce activation thresholds for autoreactive clones. Women with SLE who use exogenous estrogen-containing contraceptives or hormone replacement therapy (HRT) show modest increases in disease activity in some observational data, though the absolute risk increase is small. A 2005 randomized trial published in Annals of Internal Medicine (the SELENA-SLEDAI oral contraceptive trial) found that oral contraceptive use in women with stable SLE produced a modest increase in mild-to-moderate flares compared to placebo, without increasing severe flares. This has implications for patients considering HRT through a telehealth platform: baseline ANA testing and rheumatology clearance are appropriate when personal or family history of connective-tissue disease is present before initiating estrogen therapy.

Thyroid Autoimmunity and ANA Co-positivity

Hashimoto thyroiditis and Graves disease are common in women and frequently accompany a mildly positive ANA. The ANA in this setting is usually low titer (1:40 to 1:80) and does not independently predict SLE. Tsirogianni et al. (2017) in Autoimmunity Reviews found thyroid autoimmune disease in 14-21% of SLE patients, but the converse, a new SLE diagnosis in someone presenting with thyroid autoimmunity alone, is uncommon. A provider who identifies both thyroid autoantibodies and a mildly positive ANA should document the clinical picture carefully rather than reflexively referring for rheumatology.

GLP-1 Receptor Agonists and Autoimmune Markers

Current evidence does not associate GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) with ANA elevation or induction of autoimmune disease. The FDA labels for semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) do not list ANA elevation as an adverse effect. Post-marketing safety databases reviewed by the FDA through 2023 have not identified a signal linking GLP-1 agonist use to lupus or elevated ANA. Clinicians should still test ANA before initiating these agents in patients with symptoms suggestive of connective-tissue disease, because weight-loss-associated inflammation changes can obscure baseline autoimmune presentations.

When to Order an ANA: Clinical Indications

ANA testing is appropriate when at least one of the following is present:

• Unexplained multi-system symptoms (arthritis plus rash, plus serositis, plus renal abnormalities)
• Malar or discoid rash with no clear dermatologic explanation
• Unexplained cytopenia (low WBC, low platelets, hemolytic anemia)
• Unexplained proteinuria or hematuria in a young woman
• Photosensitivity with musculoskeletal complaints
• Raynaud phenomenon, especially onset before age 40 or with digital ulceration
• Sicca symptoms (dry eyes, dry mouth) with fatigue and arthralgia
• Suspected drug-induced lupus

Screening a completely asymptomatic individual without any of these features produces mostly low-titer positives that generate anxiety, additional testing costs, and no clinical benefit. The ACR published a Choosing Wisely recommendation against ordering ANA subserologies (anti-dsDNA, anti-Sm, etc.) in the absence of a positive ANA screen, precisely to prevent cascade testing from low-probability results.

Interpreting the Full ANA Report

A complete ANA report contains three pieces of information the ordering clinician should read together:

1. Titer. The dilution at which fluorescence is still visible. Clinically significant at 1:160 or above.
2. Pattern. The morphology of fluorescence. Guides which specific antibodies to test next.
3. Method. Whether the lab used IIF on HEp-2 cells or a solid-phase immunoassay (ELISA or multiplex bead assay). Solid-phase assays have different sensitivity and specificity profiles and may not be directly comparable to IIF results. Some labs now report ANA by solid-phase methods as "positive" or "negative" without a titer, which loses important clinical information.

If the lab report does not specify the method, the clinician should call the laboratory to confirm. A "positive ANA by ELISA" with no titer is harder to interpret than "ANA 1:320, homogeneous, IIF on HEp-2." The ACR's guidance document on ANA testing explicitly recommends IIF as the preferred method and notes that solid-phase screening assays may miss clinically significant positive results.